Compare
Gilead Sciences vs Vertex Pharmaceuticals (GILD vs VRTX)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Vertex Pharmaceuticals (VRTX) +31.2%; so far this year the figures are +36.0% and +20.7%.
Gilead Sciences is the larger company by market value, about 1.5 times the size of Vertex Pharmaceuticals.
Revenue grew +6.5% at GILD and +10.5% at VRTX over the last year.
GILD yields 1.95%. VRTX pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | VRTX | |
|---|---|---|
| Price | $166.89 | $547.09 |
| 1-day | -0.41% | +0.85% |
| YTD | +35.97% | +20.67% |
| 1 year | +36.15% | +31.20% |
| 3 years | +108.12% | +48.13% |
| Market cap | $207.0B | $138.7B |
| P/E | — | 35.2 |
| P/S | 6.68 | 10.71 |
| P/B | 15.87 | 6.63 |
| Revenue growth | +6.50% | +10.50% |
| EPS growth | -149.00% | +9.30% |
| Gross margin % | 79.9 | 85.5 |
| Net margin % | -12.5 | 30.7 |
| ROE % | -29.6 | 19.0 |
| Debt / equity | 2.01 | 0.22 |
| FCF yield % | 6.7 | 2.3 |
| Dividend yield % | 1.95 | — |
| Beta | 0.37 | 0.45 |
| RSI (14) | 60.2 | 58.0 |
| Technical rating |